Loprox and Dermatomyositis - a phase IV clinical study of FDA data
Summary:
No or few reports are found.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
No or few reports are found.
What is Loprox?
Loprox has active ingredients of ciclopirox. Currently, eHealthMe is studying from 591 Loprox users.
What is Dermatomyositis?
Dermatomyositis (inflammation of the skin and underlying muscle tissue, typically occurring as an autoimmune condition or associated with internal cancer) is found to be associated with 760 drugs and 410 conditions by eHealthMe. Currently, we are studying 7,693 people who have Dermatomyositis.
Do you take Loprox and have Dermatomyositis?
Check whether Dermatomyositis is associated with a drug or a conditionHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related studies
Loprox side effects by duration, gender and age:
- Loprox side effects (591 reports)
Dermatomyositis treatments and more:
- Dermatomyositis (7,693 reports)
All the drugs that are associated with Dermatomyositis:
All the conditions that are associated with Dermatomyositis:
How the study uses the data?
The study uses data from the FDA. It is based on ciclopirox (the active ingredients of Loprox) and Loprox (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Dilt-Cd and Breathing Difficulty - 3 seconds ago
- Jakafi and Electrocardiogram Qrs Complex Prolonged - 6 seconds ago
- Tacrolimus and Pulmonary Tuberculosis Aggravated - 24 seconds ago
- Lumigan and Tabrecta drug interaction - 26 seconds ago
- Viberzi and Tpn drug interaction - 31 seconds ago
- Loraz and Pneumonia Necrotising - 36 seconds ago
- Minocycline Hydrochloride and Norfloxacin drug interaction - 37 seconds ago
- Celebrex and Meningeal Disorder - 40 seconds ago
- Mirena and Throat Tightness - 43 seconds ago
- Metoclopramide and Nasal Congestion - 47 seconds ago